🇺🇸 LLY — Eli Lilly and Company

Healthcare Compra
← Volver

Precio actual

1.149,36 USD

Máx. histórico

1.292,65

16 días

Split 2:1 del 16/10/1997

Caída desde máximo

-11,08%

Rango 52 semanas

712,05 – 1.292,65

Variación hoy

-0,88%

Cierre anterior

1.159,60

Rango de hoy

1.138,31 – 1.158,43

Volumen hoy

2.159.931

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
38,61 (puede no estar actualizado)
Dividend yield
0,60% (puede no estar actualizado)
Precio objetivo analistas
1.315,56 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 3 días
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,58%
Fecha de pago Importe por participación
13/11/2007 0,4250 USD
13/08/2007 0,4250 USD
11/05/2007 0,4250 USD
13/02/2007 0,4250 USD
13/11/2006 0,4000 USD
11/08/2006 0,4000 USD
11/05/2006 0,4000 USD
13/02/2006 0,4000 USD
10/11/2005 0,3800 USD
11/08/2005 0,3800 USD
11/05/2005 0,3800 USD
11/02/2005 0,3800 USD
10/11/2004 0,3550 USD
11/08/2004 0,3550 USD
12/05/2004 0,3550 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
04/05/2010 35,03 35,38 34,86 35,01 -0,51% 1,48% 7.010.800
03/05/2010 35,27 35,41 35,00 35,19 +0,63% 1,16% 5.234.100
30/04/2010 35,13 35,50 34,97 34,97 -0,20% 1,51% 6.937.600
29/04/2010 34,97 35,35 34,83 35,04 +0,81% 1,49% 6.256.300
28/04/2010 35,02 35,02 34,57 34,76 -0,32% 1,28% 6.968.300
27/04/2010 35,29 35,40 34,82 34,87 -1,27% 1,64% 7.002.500
26/04/2010 35,48 35,70 35,25 35,32 -0,39% 1,27% 6.419.000
23/04/2010 35,42 35,48 34,85 35,46 +0,23% 1,78% 10.398.900
22/04/2010 35,79 35,84 35,21 35,38 -1,75% 1,76% 10.391.800
21/04/2010 36,50 36,56 35,80 36,01 -1,42% 2,08% 11.347.000
20/04/2010 36,53 36,65 36,46 36,53 -0,14% 0,52% 7.789.400
19/04/2010 35,95 36,62 35,75 36,58 +0,11% 2,42% 11.600.000
16/04/2010 36,52 36,84 36,50 36,54 -0,49% 0,93% 7.987.600
15/04/2010 36,61 36,78 36,50 36,72 +0,36% 0,76% 5.629.500
14/04/2010 36,72 36,82 36,45 36,59 -0,89% 1,01% 7.678.300
13/04/2010 36,57 36,96 36,50 36,92 +0,96% 1,26% 5.788.900
12/04/2010 36,83 36,83 36,54 36,57 -0,73% 0,79% 5.256.400
09/04/2010 36,69 36,92 36,54 36,84 +0,88% 1,04% 4.587.200
08/04/2010 36,51 36,62 36,45 36,52 +0,00% 0,47% 6.104.900
07/04/2010 36,51 36,68 36,45 36,52 +0,03% 0,63% 9.554.200
06/04/2010 36,39 36,58 36,06 36,51 -0,11% 1,43% 7.033.500
05/04/2010 36,35 36,97 36,20 36,55 +1,11% 2,12% 8.196.400
01/04/2010 36,45 36,59 36,04 36,15 -0,19% 1,51% 6.248.100
31/03/2010 35,87 36,49 35,80 36,22 +0,89% 1,92% 9.361.900
30/03/2010 35,51 35,94 35,48 35,90 +1,21% 1,30% 7.239.900
29/03/2010 35,50 35,73 35,34 35,47 +0,14% 1,10% 6.954.900
26/03/2010 36,04 36,04 35,40 35,42 -1,56% 1,78% 8.199.200
25/03/2010 36,58 36,58 35,96 35,98 -0,77% 1,69% 5.852.200
24/03/2010 36,68 36,70 36,18 36,26 -0,98% 1,42% 5.450.700
23/03/2010 36,64 36,80 36,46 36,62 +0,22% 0,93% 6.515.200